Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Reliable Biopharmaceutical (RBC), an integrated manufacturer and developer of active pharmaceutical ingredients (APIs) and high purity ingredients for pharmaceuticals and biologics, has appointed David Feldker as CEO and president of the company, effective 23 October 2010.
Subscribe to our email newsletter
RBC said that this appointment is the result of the step down of Mike Zaleski as RBC’s president and CEO effective 22 October 2010.
Prior to joining RBC, Feldker served as vice president SAFC at Sigma-Aldrich, where he was responsibility for the API contract development and manufacturing segment.
RBC chairman of the board James Breckenridge said that as RBC continues to grow, David is the perfect executive to lead RBC and capitalise on its complex chemistry capabilities, customer relationships as well as its API pipeline for generic injectable drugs.
Med Opportunity Partners co-founding partner Vicente Trelles said that they were excited about David joining their team.